Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Basel, 10 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the VENTANA Ⓡ CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive
Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed
08:07am, Wednesday, 09'th Oct 2024
Roche's CEO said on Wednesday that the Swiss drugmaker's oral drug candidate for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($11.66 billion) annually if it
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1 Findings al
David Roche says misleading 50-basis-point Fed cut will create market instability
03:44am, Monday, 07'th Oct 2024
David Roche, strategist at Quantum Strategy, says the Federal Reserve's initial jumbo cut gives markets the wrong impression that rates will return to rock bottom.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
11:05am, Tuesday, 01'st Oct 2024
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
10:00am, Tuesday, 01'st Oct 2024
Roche has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry's fas
Roche targets more than $3 billion in annual obesity sales
08:50am, Monday, 30'th Sep 2024
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billi
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
11:17am, Thursday, 26'th Sep 2024
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
01:00am, Thursday, 26'th Sep 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva®
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
01:00am, Thursday, 26'th Sep 2024
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
03:25pm, Tuesday, 24'th Sep 2024
Shares of Roche Holding AG pulled back this month after disappointing tolerability data was presented for CT-388 and CT-996 at the EASD conference. Roche sought the ceiling of safety and tolerability
Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas® Respiratory flex test, the first to use Roche's novel and proprietary TAGS (Temperature-Activate
Basel, 23 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the World Health Organization (WHO) has included dual-stain cytology testing in its cervical cancer prevention guidel
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
08:17am, Sunday, 22'nd Sep 2024
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's co
Roche Antiviral Drug Reduces Transmission in Late-stage Study
09:47am, Friday, 20'th Sep 2024
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
